Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.

Cellular signalling - 1 Nov 2013

Ueda Fumihito, Sumi Kazuya, Tago Kenji, Kasahara Tadashi, Funakoshi-Tago Megumi

Abstract excerpt

A point mutation (V617F) of tyrosine kinase Janus kinase 2 (JAK2) is found in the majority of patients with myeloproliferative neoplasms (MPNs) and an aberrant signaling pathway induced by constitutively active JAK2 V617F mutant is a hallmark of MPNs. Cells transformed by JAK2 V617F mutant exhibi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B-Lymphocytes
Share to Bleomycin
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to DNA, Neoplasm

Share to Janus Kinase 2

Share to Mitomycin

Share to STAT5 Transcription Factor

Source

Identifiers

PMID: 23838005
DOI: 10.1016/j.cellsig.2013.07.003

Genes

JAK2
FANCC
BLM
FANCD2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23838005-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.PMID 23838005Read ↗

A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations.Semantic proximity Read ↗

Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.Semantic proximity Read ↗

FANCD1/BRCA2 Plays Predominant Role in the Repair of DNA Damage Induced by ACNU or TMZSemantic proximity Read ↗

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.Semantic proximity Read ↗

Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.Semantic proximity Read ↗

Emerging functions of the Fanconi anemia pathway at a glance.Semantic proximity Read ↗

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.Semantic proximity Read ↗

FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cellsSemantic proximity Read ↗

SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells.Semantic proximity Read ↗

The phenotype of FancB-mutant mouse embryonic stem cells.Semantic proximity Read ↗

Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.Semantic proximity Read ↗

[Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.